Niagen Bioscience (NAGE) Cash from Financing Activities (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Cash from Financing Activities data on file, last reported at -$2.3 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$2.3 million, down 173.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 82.08% YoY), and the FY2025 annual result was $6.9 million, up 28.81% from the prior year.
• Cash from Financing Activities retreated to -$2.3 million in Q1 2026 per NAGE's latest filing, from -$80000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $7.7 million in Q4 2022 and troughed at -$2.3 million in Q1 2026.
• A 5-year average of $1.0 million and a median of -$3000.0 in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 34733.33% in 2024 and fell as far as 1300.0% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $7.7 million in 2022, then sank by 100.99% to -$76000.0 in 2023, then surged by 5031.58% to $3.7 million in 2024, then plunged by 102.13% to -$80000.0 in 2025, then plunged by 2762.5% to -$2.3 million in 2026.
• Business Quant data shows NAGE's Cash from Financing Activities at -$2.3 million in Q1 2026, -$80000.0 in Q4 2025, and $148000.0 in Q3 2025.